Drug Trial News

RSS

Large trial on low-dose aspirin in diabetics

Type 2 diabetics treated with low-dose aspirin did not have a significantly lower incidence of atherosclerotic events than those who received placebo in this primary prevention trial of low-dose aspirin, according to research presented at the American Heart Association's Scientific Sessions 2008. However, sub-group analyses showed a significant reduction with aspirin in both atherosclerotic events in those over 65 years of age, and a reduction in cerebrocardiovascular deaths.

11 Nov 2008

Rivaroxaban shows promise in patients with acute coronary syndrome

Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008

Interferon eliminates specific causes of some viruses in heart failure patients, improving clinical outcomes

Giving interferon to heart failure patients with evidence of a chronic viral infection safely eliminated two viruses from their systems and reduced levels of a third virus.

11 Nov 2008

Newborn neurons in the adult brain can settle in the wrong neighborhood

In a study that could have significant consequences for neural tissue transplantation strategies, researchers at the Salk Institute for Biological Studies report that inactivating a specific gene in adult neural stem cells makes nerve cells emerging from those precursors form connections in the wrong part of the adult brain.

11 Nov 2008

Trial of investigational drug for treatment of advanced heart failure

UC San Diego Medical Center is currently enrolling patients in a Phase 2 clinical trial of an investigational drug for the treatment of advanced heart failure.

10 Nov 2008

Rheumatoid arthritis drugs too slow to stop damage

A study by New Zealand researchers has questioned the current treatment approaches for rheumatoid arthritis and say they may be too slow in controlling the start of the joint damage the disease causes.

10 Nov 2008

Resverlogix Corp shows RVX-208 demonstrates increase in functional HDL particles

Resverlogix Corp. has announced key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled "Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials" was presented by Dr. Jacques Genest.

10 Nov 2008

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

VIA Pharmaceuticals, Inc. has announced the results of two Phase 2 studies of its lead drug, VIA-2291.

10 Nov 2008

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.

10 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

Pycnogenol cuts jetlag in half

Scientists have found that Pycnogenol, a natural plant extract from the bark of pine trees, can reduce jetlag symptoms by half. Pycnogenol is the patented trade name for a water extract of the bark of the French maritime pine (Pinus pinaster ssp. atlantica), which is grown in coastal southwest France.

9 Nov 2008

Spherix starts patient recruitment in India for phase 3 diabetes trial

Spherix Incorporated reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial.

8 Nov 2008

Drug Trial News

Large trial on low-dose aspirin in diabetics

Rivaroxaban shows promise in patients with acute coronary syndrome

Interferon eliminates specific causes of some viruses in heart failure patients, improving clinical outcomes

Newborn neurons in the adult brain can settle in the wrong neighborhood

Trial of investigational drug for treatment of advanced heart failure

Rheumatoid arthritis drugs too slow to stop damage

Resverlogix Corp shows RVX-208 demonstrates increase in functional HDL particles

Santaris Pharma releases positive data on LNA-based survivin inhibitor

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

Pycnogenol cuts jetlag in half

Spherix starts patient recruitment in India for phase 3 diabetes trial

Acologix demonstrates improved bone architecture in rat model of chronic kidney disease

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

BioCis Pharma starts phase IIa clinical testing of ProtoCure in atopic dermatitis

GSK initiates major seasonal influenza vaccine efficacy trial

Wide variability in rheumatoid arthritis drug Methotrexate suggests alternative dosing should be considered

Safety and efficacy of febuxostat for gout examined

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News